Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Phase Two”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)WithdrawnNCT02584777
What this trial is testing

A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis

Who this might be right for
Primary Myelofibrosis
Baxalta now part of Shire
Testing effectiveness (Phase 2)UnknownNCT03219775
What this trial is testing

Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma

Who this might be right for
Transitional Cell CarcinomaAdvanced CancerMetastatic Cancer
AIO-Studien-gGmbH 169
Testing effectiveness (Phase 2)Study completedNCT01533181
What this trial is testing

Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer

Who this might be right for
Recurrent Small Cell Lung Carcinoma
National Cancer Institute (NCI) 44
Testing effectiveness (Phase 2)Study completedNCT01553019
What this trial is testing

Postoperative Proton Radiotherapy With Chemo for Pancreatic Cancer

Who this might be right for
Pancreatic Cancer
University of Florida 2
Testing effectiveness (Phase 2)Study completedNCT05412030
What this trial is testing

Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants

Who this might be right for
Pneumonia, BacterialPneumococcal InfectionsPneumonia, Pneumococcal
GlaxoSmithKline 388
Testing effectiveness (Phase 2)Looking for participantsNCT05498428
What this trial is testing

Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-small-Cell Lung
Janssen Research & Development, LLC 520
Testing effectiveness (Phase 2)UnknownNCT05875428
What this trial is testing

Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Who this might be right for
Diffuse Large B-Cell Lymphoma
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 104
Early research (Phase 1)Study completedNCT01851265
What this trial is testing

D081AC00001 Food Interaction With Olaparib Capsule in Patients With Solid Tumours

Who this might be right for
Solid Tumours
AstraZeneca 32
Testing effectiveness (Phase 2)Ended earlyNCT03237611
What this trial is testing

Low Dose Aprepitant for Patients Receiving Carboplatin

Who this might be right for
Chemotherapy-induced Nausea and Vomiting
Albert Einstein College of Medicine 15
Testing effectiveness (Phase 2)Study completedNCT00006471
What this trial is testing

Fenretinide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Who this might be right for
Head and Neck Cancer
M.D. Anderson Cancer Center 11
Testing effectiveness (Phase 2)Ended earlyNCT04335071
What this trial is testing

Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)

Who this might be right for
SARS-CoV-2 Infection
Insel Gruppe AG, University Hospital Bern 5
Testing effectiveness (Phase 2)Study completedNCT02483234
What this trial is testing

Psoriasis-Arthritis & Bone Program

Who this might be right for
PsoriasisPsoriatic Arthritis
University of Erlangen-Nürnberg Medical School 40
Testing effectiveness (Phase 2)Looking for participantsNCT04901234
What this trial is testing

Adaptive RadioTherapy for OroPharynx Cancer

Who this might be right for
Oropharynx CancerRadiotherapy; ComplicationsRadiotherapy Side Effect+2 more
Centre hospitalier de l'Université de Montréal (CHUM) 120
Testing effectiveness (Phase 2)Study completedNCT00879034
What this trial is testing

Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria

Who this might be right for
ProgeriaHutchinson-Gilford Syndrome
Boston Children's Hospital 5
Testing effectiveness (Phase 2)Looking for participantsNCT05868395
What this trial is testing

Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma

Who this might be right for
Mantle-cell Lymphoma
Medical University of Vienna 16
Testing effectiveness (Phase 2)Looking for participantsNCT06897475
What this trial is testing

LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

Who this might be right for
Type 2 Diabetes
Eli Lilly and Company 200
Testing effectiveness (Phase 2)Study completedNCT00003957
What this trial is testing

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Fox Chase Cancer Center 3
Large-scale testing (Phase 3)Study completedNCT01631357
What this trial is testing

Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer

Who this might be right for
Non-small Cell Lung CancerSquamous Cell Carcinoma
Tianjin Medical University Cancer Institute and Hospital 96
Testing effectiveness (Phase 2)Study completedNCT00000819
What this trial is testing

A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Efficacy of Prednisone Therapy in HIV-Associated Nephropathy (HIVAN)

Who this might be right for
HIV InfectionsAIDS-Associated Nephropathy
National Institute of Allergy and Infectious Diseases (NIAID) 54
Testing effectiveness (Phase 2)Looking for participantsNCT07537400
What this trial is testing

Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5

Who this might be right for
High-Risk Neuroblastoma
Shaare Zedek Medical Center 10
Next Page